Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDOMAX: Bivalirudin vs Heparin in Peripheral Endovascular Interventions
NCT01913483Phase 3Terminated
- Sponsor
- The Medicines Company
- Start
- Sep 2013
- Primary completion
- Mar 2016
- Countries
- 1
01
Overview
A Phase 3 trial of bivalirudin in Peripheral Arterial Disease (PAD), carotid artery disease, sponsored by The Medicines Company. Started Sep 2013; status: terminated.
02
Drugs
bivalirudin
03
Conditions
Peripheral Arterial Disease (PAD)carotid artery disease
Beyond the preview
Go deeper on NCT01913483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01913483.